GlassScriptPhysician profile
Jincy Clement
NPI 1447484225
$3,068.72
in general payments reported to CMS, 2019-2025
46 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $72.93 · 2021: $311 · 2022: $513 · 2023: $1,351 · 2024: $183 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.15 |
| Education | $261.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $481.64 | 2021-2024 | |
| Accord Healthcare, INC. | $315.06 | 2023 | |
| Aveo Pharmaceuticals, INC. | $203.79 | 2022-2025 | Fotivda |
| Merck Sharp & Dohme LLC | $165.28 | 2023-2025 | Keytruda, Lynparza |
| Pfizer INC. | $148.86 | 2019-2024 | |
| Amgen INC. | $146.53 | 2022-2023 | Kyprolis, Vectibix, Xgeva |
| Novartis Pharmaceuticals Corporation | $110.63 | 2022-2025 | |
| Acrotech Biopharma INC. | $88.16 | 2021-2023 | Beleodaq |
| Astrazeneca Pharmaceuticals LP | $86.87 | 2023-2025 | Lynparza, Enhertu, Tagrisso |
| Incyte Corporation | $84.35 | 2022-2025 | Monjuvi, Jakafi |
| Janssen Biotech, INC. | $83.70 | 2020-2025 | Rybrevant, Imbruvica, Darzalex |
| Genzyme Corporation | $79.22 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $74.79 | 2019-2023 | Epkinly, Imbruvica |
| Astellas Pharma US INC | $65.51 | 2019-2025 | Vyloy |
| Eisai INC. | $64.87 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jincy Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.